Nasus Pharma Ltd.宣布其Ns002二期临床研究获得积极顶线结果。数据显示,该药物在肾上腺素递送速度方面显著优于Epipen®,能更快达到治疗阈值。
研究证实Ns002实现了更高效的药物输送机制,为过敏急救治疗提供了新的技术突破。该进展标志着公司在该治疗领域取得重要里程碑。
Nasus Pharma Ltd.宣布其Ns002二期临床研究获得积极顶线结果。数据显示,该药物在肾上腺素递送速度方面显著优于Epipen®,能更快达到治疗阈值。
研究证实Ns002实现了更高效的药物输送机制,为过敏急救治疗提供了新的技术突破。该进展标志着公司在该治疗领域取得重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.